CompletedPHASE1, PHASE2NCT00556452

Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Michigan Rogel Cancer Center
Principal Investigator
John Magenau, M.D.
University of Michigan, Department of Internal Medicine, Blood and Marrow Transplant Program
Intervention
Clofarabine/Busulfan x 4(drug)
Enrollment
46 enrolled
Eligibility
70 years · All sexes
Timeline
20072012

Study locations (1)

Collaborators

Genzyme, a Sanofi Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00556452 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials